Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Related Experiment Video

Updated: Jul 12, 2025

Analysis of Cell Cycle Position in Mammalian Cells
12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

60.5K

Sungsoo Kim1, Jessica Armand1, Anton Safonov2

  • 1Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.

Cell Reports
|October 22, 2023
PubMed

Insights

Breast cancer cells develop resistance to CDK4/6 inhibitors through a two-step E2F activation process involving Rb-protein degradation and c-Myc amplification. Higher c-Myc levels correlate with poor treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are vital for treating metastatic hormone-receptor-positive breast cancer.
  • Drug resistance to CDK4/6i poses a significant challenge to long-term treatment efficacy.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To elucidate the sequential molecular mechanisms underlying the development of CDK4/6 inhibitor resistance in breast cancer.
  • To investigate the roles of retinoblastoma (Rb) protein and c-Myc in mediating resistance.
  • To identify potential therapeutic strategies to overcome CDK4/6i resistance.

Main Methods:

  • Analysis of cell proliferation and protein levels (Rb, c-Myc) in response to CDK4/6i treatment.
  • Investigating the impact of mitogenic and hormone signaling on E2F activity and c-Myc stabilization.
  • Correlating pre-treatment c-Myc and Rb levels with therapeutic outcomes in patient tumor samples.

Main Results:

  • Breast cancer cells acquire resistance via a two-step process: Rb-protein degradation followed by c-Myc-amplified E2F transcriptional activity.
  • CDK4/6i treatment reduces Rb levels, but resistance requires additional stabilization of c-Myc, often through upregulated signaling pathways.
  • Elevated pre-treatment c-Myc levels, not Rb levels, strongly correlate with poor response to CDK4/6i therapy.

Conclusions:

  • Resistance to CDK4/6 inhibitors is driven by a sequential E2F activation pathway dependent on Rb degradation and c-Myc stabilization.
  • c-Myc levels are a critical determinant of therapeutic outcome in patients treated with CDK4/6i.
  • Proteasome inhibitors may represent a viable strategy to restore Rb levels and potentially reverse CDK4/6i resistance.
Keywords:
CDK4/6 inhibitorsCP: CancerE2F transcription factorsbreast cancerdrug resistanceretinoblastoma protein

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

130
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K